GENFIT Stock Deutsche Boerse AG
Stocks
XUP
FR0004163111
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.04 EUR | -3.26% |
|
-3.55% | +148.62% |
| 07-03 | Genfit soars on news of U.S. reimbursement for a product |  |
| 07-03 | Genfit's Liver Disease Blood Test Approved for US Medicare Reimbursement | MT |
| Market Cap | 679M 779M 634M 583M 1.09B 74.24B 1.12B 7.51B 2.94B 36.96B 2.92B 2.86B 127B | P/E 2026 * |
35x | P/E 2027 * | 90.2x |
|---|---|---|---|---|---|
| Enterprise Value | 628M 721M 586M 539M 1.01B 68.65B 1.04B 6.95B 2.72B 34.18B 2.7B 2.64B 118B | EV / Sales 2026 * |
6.27x | EV / Sales 2027 * | 4.94x |
| Free-Float |
86.88% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -3.26% | ||
| 1 week | -3.55% | ||
| Current month | +24.19% | ||
| 1 month | +38.58% | ||
| 3 months | +61.99% | ||
| 6 months | +134.11% | ||
| Current year | +148.62% |
| 1 week | 13.04 |  | 13.48 |
| 1 month | 10.18 | | 14.02 |
| Current year | 5.08 | | 14.02 |
| 1 year | 3.01 | | 14.02 |
| 3 years | 2.8 | | 14.02 |
| 5 years | 2.74 | | 14.02 |
| 10 years | 2.74 | | 33.76 |
| Manager | Title | Age | Since |
|---|---|---|---|
Pascal Prigent
CEO | Chief Executive Officer | 58 | 16/09/2019 |
Thomas Baetz
DFI | Director of Finance/CFO | 52 | 22/04/2021 |
Pejvack Motlagh
CTO | Chief Tech/Sci/R&D Officer | - | 27/11/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | 16/06/2017 | |
| Director/Board Member | 54 | 15/09/1999 | |
| Director/Board Member | 58 | 16/06/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.26% | -3.55% | - | - | 752M | |
| +2.61% | +1.91% | +1.70% | +13.91% | 47.88B | |
| -1.60% | -1.29% | +385.56% | +603.70% | 39.09B | |
| -0.98% | +2.68% | +11.10% | +45.34% | 36.75B | |
| +1.90% | +22.79% | +25.18% | +9.47% | 40.55B | |
| +1.47% | +4.90% | +6.48% | +43.52% | 27.96B | |
| -0.94% | -1.23% | - | - | 16.77B | |
| +2.44% | +10.02% | +29.11% | +129.56% | 15.94B | |
| +0.18% | -1.46% | +4.92% | +10.14% | 13.55B | |
| -1.14% | +6.94% | -6.05% | -29.33% | 13.81B | |
| Average | +0.07% | +4.66% | +57.25% | +103.29% | 28.03B | |
| Weighted average by Cap. | +0.60% | +5.06% | +73.07% | +124.52% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 100M 115M 93.54M 85.97M 161M 10.95B 165M 1.11B 433M 5.45B 431M 422M 18.78B | 124M 142M 116M 106M 200M 13.56B 204M 1.37B 536M 6.75B 534M 522M 23.25B |
| Net income | 22.88M 26.24M 21.36M 19.63M 36.84M 2.5B 37.72M 253M 98.89M 1.24B 98.41M 96.29M 4.29B | 6.8M 7.8M 6.35M 5.83M 10.95M 743M 11.21M 75.21M 29.39M 370M 29.25M 28.62M 1.27B |
| Net Debt | -51.12M -58.63M -47.72M -43.86M -82.32M -5.59B -84.27M -565M -221M -2.78B -220M -215M -9.58B | -66.17M -75.9M -61.78M -56.78M -107M -7.23B -109M -732M -286M -3.6B -285M -279M -12.4B |
| Date | Price | Change |
|---|---|---|
| 29/07/26 | €13.04 | -3.26% |
| 28/07/26 | €13.48 | +0.45% |
| 27/07/26 | €13.42 | +2.44% |
| 24/07/26 | €13.10 | 0.00% |
| 23/07/26 | €13.10 | -6.56% |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GNFT Stock
- XUP Stock
Select your edition
All financial news and data tailored to specific country editions
